Testing how genes affect blood pressure response to salt intake and saline infusion
Tests low-salt diet, high-salt diet, and saline infusion in adults with high blood pressure.
Key facts
- Who runs it
- University of Alabama at Birmingham
- Where
- Birmingham, United StatesSee the site
- Trial code
- Registry title
- Genetic Architecture of Natriuretic Peptides and Blood Pressure Response
- Status
- Not yet recruiting
- People taking part
- 200 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 1 Dec 2030
- Type of study
- Interventional, 2 groups
- Treatments tested
- Low Salt Diet
- High Salt Diet
- Saline Infusion
- Record updated
- 10 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage I or II high blood pressure who agree to give genetic material and follow the study plan.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Stage I/II hypertension (systolic blood pressure 130-159 and diastolic 80-99 mm Hg).
- Earlier treatment
- People taking 2 or more blood pressure medicines at screening cannot join.
Main reasons for not taking part
- Body mass index (BMI) above 45 kg/m2
- Uncontrolled high blood pressure (160 or higher systolic and/or 100 or higher diastolic)
- Major heart or brain disease, such as heart attack, angina, arrhythmia, heart failure, stroke, TIA or seizure
- Kidney disease, or insulin-requiring diabetes
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age more than or equal to 18 years
- Consenting to collection of genetic material and willing to adhere to study protocol
- Stage I/II Hypertension (Systolic blood pressure: 130-159 and Diastolic blood pressure: 80-99 mm Hg)
Who cannot take part
- If taking more than or equal to 2 blood pressure medications at the time of screening
- History of uncontrolled hypertension (i.e., Systolic blood pressure more than or equal to 160 mmHg and/or Diastolic blood pressure more than or equal to 100 mmHg)
- Present or past history of major cardiovascular disease including myocardial infarction, angina, cardiac arrhythmia, heart failure, stroke, transient ischemic attack, or seizure
- History of kidney disease
- History of insulin requiring diabetes
- Estimated glomerular filtration rate less than 60ml/min/1.73 m2, albumin creatinine ratio more than or equal to 30 mg/g
- Hepatic transaminase levels more than 3 times the upper limit of normal
- Anemia (men, Hb less than 13 g/dL; women, Hb less than 12 g/dL)
- Body mass index (BMI) more than 45 kg/m2
- Systolic blood pressure more than 180 and/or Diastolic blood pressure more than or equal to 120 mmHg at any point in the study
- Pregnant or breastfeeding individuals
Where in United States
- University of Alabama at BirminghamBirmingham, United StatesContact: Nehal Vekariya, MSNot yet recruiting
About the trial
What the trial wants to find out
Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.
The 2 groups in the trial
- High Natriuretic Peptide Polygenic ScoreTreatment being tested
Active Comparator: High NP PGS Group
Treatment: Low Salt Diet, High Salt Diet, and Saline Infusion
- Low Natriuretic Peptide Polygenic ScoreTreatment being tested
Experimental: Low NP PGS Group
Treatment: Low Salt Diet, High Salt Diet, and Saline Infusion
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Genetic Architecture of Natriuretic Peptides and Blood Pressure Response
- Plain-language title
- Testing how genes affect blood pressure response to salt intake and saline infusionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 March 2026